Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta, Domenico; Ceramella, Jessica; Baldino, Noemi; Sinicropi, Maria Stefania; Catalano, Alessia

doi:10.3390/ijms24043643

Cited by 29 publications

(15 citation statements)

References 283 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This resistance is often linked to inactive CYP2D6, the key enzyme responsible for converting tamoxifen to its active form, endoxifen, as well as the absence of ERα expression in cancer cells. It's interesting to note that tamoxifen-resistant breast carcinoma cells activate both canonical and noncanonical Wnt signaling systems 66 . The Wnt signaling protein Wnt3a further increases the resistance of ER+ carcinoma cells to tamoxifen therapy.…”

Section: Drug Sensitivity and Wnt Activation In Breast Cancermentioning

confidence: 99%

Navigating breast cancer complexity: Deciphering the cross talk of Wnt/β catenin and Notch pathways in development and diseases

Rasool,

Bhat,

Khurshid

et al. 2024

Preprint

View full text Add to dashboard Cite

This study investigates miRNA impact on lung, colorectal, and epithelial cancers, emphasizing Wnt3’s role in breast tumor growth through WNT signaling and its influence on mammary stem cells. WNT pathway inactivation induces drug-insensitive, quiescent states in breast cancer stem cells, resulting in resistance to multiple drugs. Tamoxifen-resistant breast carcinoma cells activate both canonical and noncanonical WNT signaling, with Wnt3a enhancing tamoxifen resistance in ER+ carcinoma cells. The study also explores breast cancer immunotherapy, highlighting immune checkpoint blockade targeting PD-1/PD-L1 and CTLA-4 as promising avenues. Additionally, the study explores the NOTCH signaling pathways impact on cancer proliferation, apoptosis, invasion and metastasis. Elevated NOTCH receptor and ligand expression particularly in aggressive triple negative breast cancer correlate with poorer treatment outcome, serving as a predictor for adverse results in breast tumors. The review discusses the relevance of Notch signaling in therapy resistance and breast cancer recurrence. The article encapsulates therapeutic advancements targeting the Notch signaling pathway, weighing merits and demerits in the context of breast cancer treatment. Our study provides a comprehensive understanding of the complex interactions within the WNT and Notch signaling pathways in breast cancer, shedding light on potential therapeutic targets and strategies for personalized treatment. This research significantly contributes to the current body of knowledge, offering promise for improved outcomes in breast cancer patients. The findings underscore the importance of WNT and Notch signaling modulation in developing effective therapeutic interventions for breast cancer.

show abstract

Section: Drug Sensitivity and Wnt Activation In Breast Cancermentioning

confidence: 99%

Navigating breast cancer complexity: Deciphering the cross talk of Wnt/β catenin and Notch pathways in development and diseases

Rasool,

Bhat,

Khurshid

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Tamoxifen (Figure 12) is a well-known anticancer drug belonging to selective estrogen-receptor modulators (SERMs) used in the treatment of early and metastatic hormone receptor-positive breast cancer [89]. It is a prodrug, which is metabolized via the CYP enzymes to the more active primary metabolites N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and the secondary metabolite endoxifen (N-desmethyl-4-hydroxy-tamoxifen) that are responsible for the anticancer activity [90].…”

Section: Tamoxifenmentioning

confidence: 99%

Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs

et al. 2023

Self Cite

View full text Add to dashboard Cite

The cytochrome P450 (CYP) enzyme family is the major enzyme system catalyzing the phase I metabolism of xenobiotics, including pharmaceuticals and toxic compounds in the environment. A major part of the CYP-dependent xenobiotic metabolism is due to polymorphic and inducible enzymes, which may, quantitatively or qualitatively, alter or enhance drug metabolism and toxicity. Drug–drug interactions are major mechanisms caused by the inhibition and/or induction of CYP enzymes. Particularly, CYP monooxygenases catalyze hydroxylation reactions to form hydroxylated metabolites. The secondary metabolites are sometimes as active as the parent compound, or even more active. The aim of this review is to summarize some of the significative examples of common drugs used for the treatment of diverse diseases and underline the activity and/or toxicity of their metabolites.

show abstract

“…However, high ERα levels in ER‐positive BCs can play a role in tumor progression and resistance to hormonal therapy. SAHA has shown potential in depleting ERα and inhibiting cancer cell proliferation in ER‐positive BCs (Iacopetta et al, 2023). It triggers cell cycle arrest in luminal and TNBC cell lines, leading to apoptosis and cell cycle arrest in the G1 phase, with stronger effects observed in T47D ER+ cells (Lee et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils

Senthilkumar,

Gogoi,

Dhan

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

Epigenetic modifications play a significant role in cancer progression, making them potential targets for therapy. Histone deacetylase inhibitors have shown promise in inhibiting cancer cell growth, including in breast cancer (BC). In this research, we examined the potential of using suberoyl anilide hydroxamic acid (SAHA)‐loaded β‐lg nanofibrils as a drug delivery system for triple‐negative BC cell lines. We assessed their impact on cell cycle progression, apoptosis, levels of reactive oxygen species, and mitochondrial membrane potential in cancer cells. The combination of SAHA and β‐lg nanofibrils demonstrated enhanced efficacy in inhibiting cell growth, inducing cell cycle arrest, and promoting apoptosis (43.78%) compared to SAHA alone (40.09%). Moreover, it effectively targeted cancer cells without promoting drug resistance while using a low concentration of the nanofibrils. These findings underscore the promising potential of nanofibril‐based drug delivery systems for BC treatment.

show abstract

Targeting Breast Cancer: An Overlook on Current Strategies

Cited by 29 publications

References 283 publications

Navigating breast cancer complexity: Deciphering the cross talk of Wnt/β catenin and Notch pathways in development and diseases

Navigating breast cancer complexity: Deciphering the cross talk of Wnt/β catenin and Notch pathways in development and diseases

Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs

Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils

Contact Info

Product

Resources

About